We TMS have been striving and evolving our business by focusing on research and development of a family of small molecule compounds called SMTPs (stachybotrys microspora triprenyl phenols), initially discovered as a microbial metabolite at Tokyo University of Agriculture and Technology.
Our efforts have led to promising results, both in efficacy and safety, of Phase 2a clinical trial of TMS-007, which we believe to bring about a significant change to treatment of acute ischemic stroke. We are proudly engaged in further development of TMS-007, which we have been involved since the research stage all the way till present.
Our research and development experience with SMTP compounds has been numerous successions of experiments, various findings based on detailed analyses, and careful examination of evidence. It’s been a process to pursue truth in foggy sea of information.
Elaborate approach to drug discovery like this is becoming scarce in the pharmaceutical industry of today. We believe, however, that we can create substantial business opportunities by repeating and further advancing this classic approach.
Following TMS-007, we are developing TMS-008, indicated for acute kidney injury, and JX09, indicated for resistant hypertension, among others. We will continue efforts to develop these compounds for the indications with which medical needs are not sufficiently met.
We also envision to strengthen our portfolio by actively cooperating with external scientists, which we have been already in action. We continue striving to deliver breakthrough pharmaceutical products to patients by working through these approaches.
Takuro Wakabayashi
Chief Executive Officer
